| 摘要 |
<p>The invention relates to compounds of general formula (I) wherein R1 is hydrogen or halogen; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is halogen, trifluoromethyl, lower alkoxy or lower alkyl; R4/R4' are independently from each other hydrogen or lower alkyl; R5 is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, -(CH2)n-piperazinyl, optionally substituted by lower alkyl, -(CH2)n-morpholinyl, -(CH2)n+1-imidazolyl, -O-(CH2)n+1-morpholinyl, -O-(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH2)n+1N(R4")2, -(CH2)n-NH-(CH2)n+1N(R4")2, -(CH2)n+1N(R4")2, or -O-(CH2)n+1N(R4")2, wherein R4" is hydrogen or lower alkyl; R6 is hydrogen; R2 and R6 or R1 and R6 may be together with the two carbon ring atoms -CH=CH-CH=CH-, with the proviso that n for R1 is 1; n is independently 0 - 2; and X is -C(O)N(R4")- or -N(R4")C(O)-; and pharmaceutically acceptable acid addition salts thereof. Compounds of formula (I) have a high affinity to the NK-1 receptor. They are therefore useful for the treatment or diseases which relate to this receptor.</p> |
